Body Mass Index and Melanoma Prognosis
Keywords:
cutaneous melanoma, body mass index, Breslow thickness, obesityAbstract
Introduction: Obesity has been suggested as a risk factor in the progression of malignancies, including melanoma. Most studies defined obesity using body mass index (BMI), although the index is considered an imperfect measure of body composition.
Objective: The aim of this article is to examine whether BMI can impact the prognosis of cutaneous melanoma, regardless of anti-tumor therapy. The relationship between BMI and specific prognostic factors in melanoma patients has been reviewed.
Methods: Literature search was conducted on PubMed using the terms “melanoma” and “body mass index” or “obesity”. We selected articles, published up to 30 November 2020, examining the prognostic aspects of melanoma. Articles evaluating the risk and incidence of melanoma were excluded as well as studies regarding morbidity and complications following surgical procedures, or those performed in metastatic melanoma patients treated with anti-tumor therapies.
Results: Mixed results have emerged from studies assessing the clinical outcomes in melanoma patients in relation to BMI. More consistent data seem to support the relationship between BMI and Breslow thickness.
Conclusions: Studies that focus specifically on the link between obesity and melanoma prognosis are limited; further research is needed to deepen our knowledge on this link.
References
Avgerinos KI, Spyrou N, Mantzoros CS, Dalamaga M. Obesity and cancer risk: Emerging biological mechanisms and perspectives. Metabolism. 2019;92:121-135. DOI: 10.1016/j.metabol.2018.11.001. PMID: 30445141.
Bandera EV, Fay SH, Giovannucci E, et al; World Cancer Research Fund International Continuous Update Project Panel. The use and interpretation of anthropometric measures in cancer epidemiology: A perspective from the world cancer research fund international continuous update project. Int J Cancer. 2016;139(11):2391-2397. DOI: 10.1002/ijc.30248. PMID: 27352197.
Hopkins BD, Goncalves MD, Cantley LC. Obesity and cancer mechanisms: Cancer metabolism. J Clin Oncol. 2016;34(35):4277-4283. DOI: 10.1200/JCO.2016.67.9712. PMID: 27903152.
Smith LK, Arabi S, Lelliott EJ, McArthur GA, Sheppard KE. Obesity and the impact on cutaneous melanoma: Friend or foe? Cancers (Basel). 2020;12(6):1583. DOI: 10.3390/cancers12061583. PMID: 32549336.
Clement E, Lazar I, Muller C, Nieto L. Obesity and melanoma: could fat be fueling malignancy? Pigment Cell Melanoma Res. 2017;30(3):294-306. DOI: 10.1111/pcmr.12584. PMID: 28222242.
McQuade J, Daniel C, Hess KR, et al. Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. Lancet Oncol. 2018;19(3):310–322. DOI: 10.1016/S1470-2045(18)30078-0.
Wang Z, Aguilar E, Luna J, et al. Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade. Nat Med. 2019;25(1):141-151. DOI: 10.1038/s41591-018-0221-5.
Donnelly D, Bajaj S, Yu J, et al. The complex relationship between body mass index and response to immune checkpoint inhibition in metastatic melanoma patients. J Immunother Cancer. 2019;7(1):222. DOI: 10.1186/s40425-019-0699-5. PMID: 31426863.
Rutkowski P, Indini A, De Luca M, et al. Body mass index (BMI) and outcome of metastatic melanoma patients receiving targeted therapy and immunotherapy: a multicenter international retrospective study. J Immunother Cancer. 2020;8(2):e001117. DOI: 10.1136/jitc-2020-001117. PMID: 33203662.
Reeves GK, Pirie K, Beral V, Green J, Spencer E, Bull D; Million Women Study Collaboration. Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ. 2007;335(7630):1134. DOI: 10.1136/bmj.39367.495995.AE. PMID: 17986716.
Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348(17):1625-1638. DOI: 10.1056/NEJMoa021423. PMID: 12711737.
Moliterni E, Paolino G, Veronese N, et al. Prognostic correlation between vitamin D serological levels, Body Mass Index and clinical-pathological features in melanoma patients. G Ital Dermatol Venereol. 2018;153(5):732-733. DOI: 10.23736/S0392-0488.17.05652-8. PMID: 30246955.
Hardie CM, Elliott F, Chan M, Rogers Z, Bishop DT, Newton-Bishop JA. Environmental exposures such as smoking and low vitamin D are predictive of poor outcome in cutaneous melanoma rather than other deprivation measures. J Invest Dermatol. 2020;140:327-337.e2. DOI: 10.1016/j.jid.2019.05.033. PMID: 31425707.
Beswick S, Affleck P, Elliott F, et al. Environmental risk factors for relapse of melanoma. Eur J Cancer. 2008;44(12):1717-1725. DOI: 10.1016/j.ejca.2008.05.007. PMID: 18602256.
Oba J, Wei W, Gershenwald JE, et al. Elevated serum leptin levels are associated with an increased risk of sentinel lymph node metastasis in cutaneous melanoma. Medicine (Baltimore). 2016;95(11):e3073. DOI: 10.1097/MD.0000000000003073. PMID: 26986135.
Newton-Bishop JA, Davies JR, Latheef F, et al. 25-Hydroxyvitamin D2 /D3 levels and factors associated with systemic inflammation and melanoma survival in the Leeds Melanoma Cohort. Int J Cancer. 2015;136(12):2890-2899. DOI: 10.1002/ijc.29334. PMID: 25403087.
Newton-Bishop JA, Beswick S, Randerson-Moor J, et al. Serum 25-hydroxyvitamin D3 levels are associated with Breslow thickness at presentation and survival from melanoma. J Clin Oncol. 2009;27(32):5439-5444. DOI: 10.1200/JCO.2009.22.1135. PMID: 19770375.
Fang S, Wang Y, Dang Y, et al. Association between body mass index, C-reactive protein levels, and melanoma patient outcomes. J Invest Dermatol. 2017;137(8):1792-1795. DOI: 10.1016/j.jid.2017.04.007. PMID: 28442307.
Kim JE, Chung BY, Sim CY, et al. Clinicopathologic features and prognostic factors of primary cutaneous melanoma: a multicenter study in Korea. J Korean Med Sci. 2019;34(16):e126. DOI: 10.3346/jkms.2019.34.e126. PMID: 31020815.
World Health Organization IOTF. The Asian-Pacific perspective: Redefining obesity and its treatment. Geneva: WHO Western Pacific Region, 2000.
de Giorgi V, Gori A, Papi F, et al. Excess body weight and increased Breslow thickness in melanoma patients: a retrospective study. Eur J Cancer Prev. 2013;22(5):480-485. DOI: 10.1097/CEJ.0b013e32835f3b5d. PMID: 23462459.
Gandini S, Montella M, Ayala F, et al; Clinical National Melanoma Registry Group. Sun exposure and melanoma prognostic factors. Oncol Lett. 2016;11(4):2706-2714. DOI: 10.3892/ol.2016.4292. PMID: 27073541.
Skowron F, Bérard F, Balme B, Maucort-Boulch D. Role of obesity on the thickness of primary cutaneous melanoma. J Eur Acad Dermatol Venereol. 2015;29(2):262-269. DOI: 10.1111/jdv.12515. PMID: 24750303.
Stenehjem JS, Veierød MB, Nilsen LT, et al. Anthropometric factors and Breslow thickness: prospective data on 2570 cases of cutaneous melanoma in the population-based Janus Cohort. Br J Dermatol. 2018;179(3):632-641. DOI: 10.1111/bjd.16825. PMID: 29858512.
Wyatt C, Lucas RM, Hurst C, et al. Vitamin D deficiency at melanoma diagnosis is associated with higher Breslow thickness. PLoS One. 2015;10(5):e0126394. DOI: 10.1371/journal.pone.0126394. PMID: 25970336.
von Schuckmann LA, Smith D, Hughes MCB, et al. Associations of statins and diabetes with diagnosis of ulcerated cutaneous melanoma. J Invest Dermatol. 2017;137(12):2599-2605. DOI: 10.1016/j.jid.2017.07.836. PMID: 28842323.
Cauci S, Maione V, Buligan C, Linussio M, Serraino D, Stinco G. BsmI (rs1544410) and FokI (rs2228570) vitamin D receptor polymorphisms, smoking, and body mass index as risk factors of cutaneous malignant melanoma in northeast Italy. Cancer Biol Med. 2017;14(3):302-318. DOI: 10.20892/j.issn.2095-3941.2017.0064. PMID: 28884047.
Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371(9612):569-578. DOI: 10.1016/S0140-6736(08)60269-X.
Sergentanis TN, Antoniadis AG, Gogas HJ, et al. Obesity and risk of malignant melanoma: a meta-analysis of cohort and case-control studies. Eur J Cancer. 2013;49(3):642-657. DOI: 10.1016/j.ejca.2012.08.028. PMID: 23200191.
Dobbins M, Decorby K, Choi BC. The association between obesity and cancer risk: a meta-analysis of observational studies from 1985 to 2011. ISRN Prev Med. 2013:680536. DOI: 10.5402/2013/680536. PMID: 24977095.
Præstegaard C, Kjær SK, Christensen J, Tjønneland A, Halkjær J, Jensen A. Obesity and risks for malignant melanoma and non-melanoma skin cancer: results from a large Danish prospective cohort study. J Invest Dermatol. 2015;135(3):901-904. DOI: 10.1038/jid.2014.438. PMID: 25290686.
Choi EK, Park HB, Lee KH, et al. Body mass index and 20 specific cancers: Re-analyses of dose-response meta-analyses of observational studies. Ann Oncol. 2018;29(3):749-757. DOI: 10.1093/annonc/mdx819. PMID: 29300814.
Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(6):472-492. DOI: 10.3322/caac.21409. PMID: 29028110.
McQuade JL, Daniel CR, Davies MA. Body-mass index and metastatic melanoma outcomes - Authors' reply. Lancet Oncol. 2018;19(5):e227-e228. DOI: 10.1016/S1470-2045(18)30266-3. PMID:
Kushiro K, Chu RA, Verma A, Núñez NP. Adipocytes promote B16BL6 melanoma cell invasion and the epithelial-to-mesenchymal transition. Cancer Microenviron. 2012;5(1):73-82. DOI: 10.1007/s12307-011-0087-2. PMID: 21892698.
Lazar I, Clement E, Dauvillier S, et al. Adipocyte exosomes promote melanoma aggressiveness through fatty acid oxidation: a novel mechanism linking obesity and cancer. Cancer Res. 2016;76(14):4051-4057. DOI: 10.1158/0008-5472.CAN-16-0651. PMID: 27216185.
Coelho P, Almeida J, Prudêncio C, Fernandes, R, Soares R. Effect of adipocyte secretome in melanoma progression and vasculogenic mimicry. J Cell Biochem. 2016;117(7):1697-1706. DOI: 10.1002/jcb.25463. PMID: 26666522.
Robado de Lope L, Alcíbar OL, Amor López A, Hergueta-Redondo M, Peinado H. Tumour-adipose tissue crosstalk: fuelling tumour metastasis by extracellular vesicles. Philos Trans R Soc Lond B Biol Sci. 2018;373(1737). DOI: 10.1098/rstb.2016.0485. PMID: 29158314.
Zhang M, Di Martino JS, Bowman RL, et al. Adipocyte-derived lipids mediate melanoma progression via FATP proteins. Cancer Discov. 2018;8(8):1006-1025. DOI: 10.1158/2159-8290.CD-17-1371. PMID: 29903879.
Clement E, Lazar I, Attané C, et al. Adipocyte extracellular vesicles carry enzymes and fatty acids that stimulate mitochondrial metabolism and remodeling in tumor cells. EMBO J. 2020;39(3):e102525. DOI: 10.15252/embj.2019102525. PMID: 31919869.
Chen J, Chi M, Chen C, Zhang XD. Obesity and melanoma: exploring molecular links. J Cell Biochem. 2013;114(9):1955-1961. DOI: 10.1002/jcb.24549. PMID: 23554059.
Pandey V, Vijayakumar MV, Ajay AK, Malvi P, Bhat MK. Diet-induced obesity increases melanoma progression: involvement of Cav-1 and FASN. Int J Cancer. 2012;130(3):497-508. DOI: 10.1002/ijc.26048. PMID: 21387314.
Malvi P, Chaube B, Pandey V, Vijayakumar MV, Boreddy PR, Mohammad N, Singh SV, Bhat MK. Obesity induced rapid melanoma progression is reversed by orlistat treatment and dietary intervention: role of adipokines. Mol Oncol. 2015;9(3):689-703. DOI: 10.1016/j.molonc.2014.11.006. PMID: 25499031.
Antoniadis AG, Petridou ET, Antonopoulos CN, et al. Insulin resistance in relation to melanoma risk. Melanoma Res. 2011;21(6):541-546. DOI: 10.1097/CMR.0b013e32834b0eeb. PMID: 21946019.
Randerson-Moor JA, Taylor JC, Elliott F, et al. Vitamin D receptor gene polymorphisms, serum 25-hydroxyvitamin D levels, and melanoma: UK case–control comparisons and a meta-analysis of published VDR data. Eur J Cancer. 2009;45(18):3271-3281. DOI: 10.1016/j.ejca.2009.06.011. PMID: 19615888.
Fang S, Sui D, Wang Y, et al. Association of vitamin D levels with outcome in patients with melanoma after adjustment for C-reactive protein. J Clin Oncol. 2016;34(15):1741–1747. DOI: 10.1200/JCO.2015.64.1357. PMID: 27001565.
Moreno-Arrones OM, Zegeer J, et al. Decreased vitamin D serum levels at melanoma diagnosis are associated with tumor ulceration and high tumor mitotic rate. Melanoma Res. 2019;29:664-667.DOI: 10.1097/CMR.0000000000000638. PMID: 31469708.
Li X, Liang LM, Zhang MF, et al. Obesity-related genetic variants, human pigmentation, and risk of melanoma. Hum Genet. 2013;132(7):793-801. DOI: 10.1007/s00439-013-1293-4. PMID: 23539184.
de Giorgi V, Sestini S, Gori A, et al. Polymorphisms of estrogen receptors: risk factors for invasive melanoma - a prospective study. Oncology. 2011;80(3-4):232-237. DOI: 10.1159/000328321. PMID: 21734414.
Santonocito C, Paradisi A, Capizzi R, Concolino P, Lavieri MM, Lanza Silveri S, De Luca D, Catricalà C, Di Carlo A, Zuppi C, Ameglio F, Capoluongo E. Insulin-like growth factor I (CA) repeats are associated with higher melanoma's Breslow index but not associated with the presence of the melanoma. A pilot study. Clin Chim Acta. 2008;390(1-2):104-9. DOI: 10.1016/j.cca.2008.01.006. PMID: 18237549.
Published
Issue
Section
License
Dermatology Practical & Conceptual applies a Creative Commons Attribution License (CCAL) to all works we publish (http://creativecommons.org/licenses/by-nc/4.0/). Authors retain the copyright for their published work.
How to Cite
Share
